sanofi

Results Q3 2024

October 25, 2024

Forward-looking statements

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "potential", "outlook", "guidance" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete capital markets or other transactions and/or obtain regulatory clearances, risks associated with developing standalone businesses, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, rends in exchange rates and prevailing interest rates, volatile economic and capital market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics, political disruption or armed conflicts or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Brand names appearing in this presentation are trademarks of Sanofi and/or its affiliates. Not all trademarks related to products under development have been approved as of the date of this presentation by the relevant health authorities.

Agenda

01 **Business**
Paul Hudson

02 **Finance**
François Roger

03 **Pipeline**
Houman Ashrafian

04 **Q&A**
Presenters and Brian Foard, Olivier Charmeil, Thomas Triomphe, Julie Van Ongevalle, and Roy Papatheodorou

Q3: *15.7% sales growth* boosted by vaccines phasing; business EPS guidance raised to reflect strong business performance



- **Dupixent:** strong growth across indications and geographies
- **Pharma launches:** strong broad-based performance
- **Vaccines:** growth partly driven by flu and Beyfortus phasing, and Beyfortus approved extra capacity
- **Opella:** growth driven by underlying performance and Qunol acquisition in the US
- **Guidance:** 2024 business EPS upgraded

All changes at CER and for Q3 2024 unless stated otherwise. 1. ALTUVIIIO, Nexviazyme, Rezurock, Sarclisa, Cablivi, Xenpozyme, Enjaymo, Tzield. Opella is the name for the business formerly known as Sanofi Consumer Healthcare.

Dupixent continues strong growth, on track for *~€13bn in 2024*

Sales (€m)



Q3 performance

Global growth of *24%* driven by strong demand

#1 NBRx market share across ALL approved indications[2]

>1,000,000 patients on therapy worldwide

Recent milestones

Regulatory approvals

- COPD in more than 30 countries
- Chronic rhinosinusitis with nasal polyposis, adolescent (US)

Positive phase 3 data readouts

- Bullous pemphigoid
- Chronic spontaneous urticaria (Study C)

All growth and Dupixent goal at CER. 1. Represents growth in Q3 2024 from Q3 2023. 2. IQVIA data with internal projection.

Dupixent: strong execution to *drive growth*

Drive market growth through *increased penetration* in biologic-eligible patients

Deepen *indication breadth* in launched countries[1]

Transform standard of care in *new indications* (COPD, BP, CSU…)

Ambition to grow sales at low *double-digit CAGR* 2023-30[2]

1. ~30 potential country approvals in 2024-2026 including AD, asthma, CRSwNP, EoE, PN. 2. Growth at CER.

New launches: contributing close to *€3bn sales* YTD

Sales (€m)	*Q3*	*YTD*
Beyfortus (nirsevimab)	645	845
ALTUVIIIO efanesoctocog alfa	172	452
MAKE YOUR NEX MOVE Nexviazyme (avalglucosidase alfa)	163	483
REZUROCK (belumosudil) tablets	131	338
SARCLISA (isatuximab-irfc)	114	341
Cablivi caplacizumab-yhdp	63	176
Xenpozyme (olipudase alfa)	41	113
Enjaymo sutimlimab-jome	28[1]	83[1]
Tzield (teplizumab-mzwv)	15	36
	€1,372m	*€2,867m*

All changes at CER and for Q3 2024 unless stated otherwise. 1. On October 4, 2024, Recordati announced the acquisition of global rights to Enjaymo. This transaction is expected to close this quarter, subject to customary closing conditions.

Beyfortus and Fluzone HD establish high-efficacy standards with the *strongest level of evidence* to date

Beyfortus® (nirsevimab)

Continuing to expand outstanding body of evidence

- Protection sustained over 180 days[1]: 83% efficacy against RSV hospitalization *new*
- 87% efficacy confirmed by recent BEAR RWE[2] *new*
- Real-world effectiveness consistently exceeding 80% reduction in hospitalization (>75k babies)[3]

Blockbuster status through "All Infant Protection"

- 2024 supply secured in 20 countries
- Recommendations for All Infant Protection in most launched countries

Influenza Vaccine Fluzone® High-Dose

Randomized controlled trials required to substantiate efficacy of influenza vaccines

- Fluzone HD demonstrated **24.2% superior efficacy vs. standard dose** (32k participants)[4]
- Alternative adjuvanted and mRNA flu vaccines have not demonstrated superior efficacy against standard dose in RCTs (ongoing studies)

Value of differentiated products supported by partners

1. Munro, A.P.S., et al. (2024). Efficacy of nirsevimab Over 6 Months: A 180-Day Endpoint Analysis from the HARMONIE Study, a Randomized Phase iiib Trial. SSRN. https://ssrn.com/abstract=4995419. 2. Klein NP, et al. Effectiveness of nirsevimab in infants against respiratory syncytial virus (RSV) and RSV-related events. Oral presentation at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; 26 October 2024; Boston, Massachusetts. BEAR: Beyfortus Effectiveness Against medically attended RSV events in infants. 3. Wick M, et al. RSV Prophylaxis with nirsevimab in infants: systematic review of early real-world evidence on effectiveness and impact. Poster presented at IDWeek on October 17th, 2024 in Los Angeles, California. 4. DiazGranados CA, et al. N Engl J Med. 2014.

Living wage *pledge*

Sanofi ensures a living wage for all its employees, going beyond minimum wage standards

Methodology established by Fairwage Network[1] to determine living wage levels

Aim	Improve employee health, well-being, and contribute positively to local economies
Overcome challenges	Navigate economic disparities between countries, cost of living variations and complex legal environments
Extended commitment	Advocate for living wage adoption among key supply chain partners

1. Fair Wage Network applies a multi-dimensional approach to drive fair wages standards with companies.

sanofi

Finance

Q3 2024

Strong *momentum* further boosted by early vaccines delivery

Sales (€m)



All changes at CER and for Q3 2024 unless stated otherwise.

Group P&L

(€m)	*Q3 2023*	*Q3 2024*	*% change*
Net sales	**11,964**	**13,438**	**+15.7%**
Other revenues	734	719	-0.7%
Gross profit	**8,858**	**10,074**	**+17.4%**
Gross margin %	74.0%[1]	75.0%[1]	+1.0pp
R&D	(1,663)	(1,852)	+12.7%
SG&A	(2,579)	(2,681)	+6.4%
Operating expenses	**(4,242)**	**(4,533)**	**+8.9%**
% of net sales	*35.5%*	*33.7%*	*-1.8pp*
Other operating income & expenses	(598)	(971)	+65.6%
Business operating income (BOI)	**4,028**	**4,607**	**+19.9%**
Business operating margin	33.7%[1]	34.3%[1]	+0.6pp
Effective tax rate	19.0%	21.0%	+2.0pp
Total business net income	**3,196**	**3,585**	**+17.5%**
Average number of shares, million	1,253.2	1,253.0	
Business EPS	**2.55**	**2.86**	**+17.6%**

Sales

+15.7%; boosted by flu and Beyfortus sales phasing; solid, underlying double-digit growth

Gross margin

+1.0pp, driven by positive mix effect, partly offset by currency and Aubagio comparison base

Operating expenses

R&D: on track for committed increase in 2024
SG&A: grew substantially less than sales

Business operating income

+19.9%, driven mainly by higher gross profit, operating leverage, offset by higher Regeneron profit share and less capital gains

EPS

+17.6%, driven by higher business net income

All changes at CER and for Q3 2024 unless stated otherwise. 1. Margin at published rate.

Business dynamics to consider for the remainder of 2024

	Sales		P&L	
Q4 2024	**Beyfortus**	Sales similar to Q3	**Other revenues**	One-off COVID-19 sales of €400m in Q4 2023
			Costs	Continued step-up in development; increased investments in S&M to support sales and digitalization
FY 2024	**Dupixent**	Target of ~€13bn	**Gross margin**	Slightly declining
	Flu	Expect low single-digit decline due to soft vaccination rate	**Costs**	Step-up in development
	Vaccines	Expect to grow high single-digit	**Capital gains (divestments)**	~€400m for Biopharma
	GenMed	Divestments ~€300m sales impact	**Tax rate**	20% (vs. 18%)[1]
			EPS Fx impact	-5.5% to -6.5%[1,2]

Guidance upgraded earlier in October: 2024 business EPS to grow by at least a low single-digit percentage[3]

Barring unforeseen events. All changes at CER unless stated otherwise. 1. Excluding Opella. 2. Based on October 2024 average rates. 3. Based on 2023 preliminary business EPS of €7.25 excluding Opella.

Sanofi in exclusive negotiation to *sell a controlling stake* of Opella

Potential transaction for a 50% controlling stake of Opella

sanofi	CD&R	bpifrance
~48%	~50%	~2%

Opella. | *EV €16bn*

Clear strategy for value creation

Sanofi to retain a significant stake and a large part of future value creation.

Sanofi to become a pure-play, science-driven biopharma company focused on innovative medicines and vaccines.

Closing of the transaction expected in *Q2 2025*[1] at the earliest.

Expected use of proceeds in line with Sanofi's existing capital-allocation priorities, including *shareholder returns*

1. The proposed transaction is subject to finalization of definitive agreements, completion of the appropriate social processes and subject to customary closing conditions.

sanofi

Pipeline



Pipeline: Q3 *milestones*

Regulatory approvals

Dupixent	COPD (US, CN), CRSwNP adolescents (US)
Sarclisa	NDMM, TI (US)

Phase 3 data readouts

Dupixent	CSU (Study C) (primary endpoint met)
	CPUO (primary endpoint not met)
	BP (primary endpoint met)
tolebrutinib	RMS (primary endpoint not met)
	nrSPMS (primary endpoint met)
Sarclisa	NDMM, TE (HD7 study) (primary endpoint met)

New business developments

- Equity investment in **MeiraGTx**, a clinical-stage genetic medicine company
- Equity investment in **Ventyx,** a clinical-stage biopharmaceutical company in autoimmune and inflammatory disorders
- Equity investment in **Anaptys**, a clinical-stage biotechnology company focused on immunology therapeutics, including in rheumatoid arthritis and ulcerative colitis
- Equity investment in **Vicore,** a clinical-stage pharmaceutical company in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis
- Exclusive licensing agreement with **RadioMedix** and **Orano Med**, for the late-stage project, AlphaMedix™ (212Pb-DOTAMTATE) in rare cancers

tolebrutinib: unprecedented *effect on disability* in nrSPMS

Primary endpoint met: 31% delay in time to onset of 6-month confirmed disability progression



US submission planned by *year-end*, followed by EU in *H1 2025*

- Number of participants who experienced confirmed disability improvement *increased by nearly two-fold with tolebrutinib* vs. placebo (HR 1.88; 95% CI, 1.10 to 3.21; p=0.021)
- tolebrutinib significantly *lowered the annualised rate of new/enlarging T2 lesions* vs. placebo (HR 0.62, 95% CI, 0.43-0.90; p=0.011)

- Liver enzyme elevations have been reported with tolebrutinib and other BTK inhibitors
- Elevations >3x ULN were observed in 4.1% of tolebrutinib participants and they *all occurred within the first 90 days of treatment*
- The vast majority of cases *resolved without sequelae*
- Frequent liver monitoring in the first 90 days has been implemented

PPMS phase 3 data readout in *H2 2025*

For additional details, please refer to the European Committee for treatment and research in Multiple Sclerosis (ECTRIMS) 2024 Congress presentation #O136 (clinical trials identifier: NCT04411641).

amlitelimab: 68-week STREAM-AD phase 2b results confirmed *long-term safety* profile in atopic dermatitis

No dose dependency in safety observed across dose arms

n (%) of participants with ≥1 TEAE	Week 0-68 part 2 safety population (n=186)		
Part 1 treatment group	**Pooled amlitelimab**	**Pooled amlitelimab**	**Placebo**
Part 2 treatment group	**Pooled amlitelimab** (n=43)	**Pooled withdrawal (placebo)** (n=128)	**Placebo** (n=15)
Any TEAE	36 (83.7)	118 (92.2)	14 (93.3)
Any SAE	2 (4.7)	3 (2.3)	0
Any TEAE leading to treatment discontinuation	1 (2.3)	0	0
Any AESI	1 (2.3)	1 (0.8)	0

- Most reported TEAEs were *mild or moderate in severity*
- Anti-drug antibody levels were generally low

Potential for *differentiated safety* in atopic dermatitis

Current clinical profile

- Effective treatment in AD across *both type-2 and non-type 2 pathways,* with broadly moderate-to-severe eligible population
- Potential for convenient *extended dosing* interval up to Q12W
- Potential for therapy-free remission through *durable efficacy* by immune memory
- Potential for *disease modification* confirmed in previous studies



OCEANA phase 3 program *ongoing* in atopic dermatitis

For additional details, please refer to the European Academy of Dermatology and Venerology (EADV) 2024 Congress presentation (clinical trials identifier: NCT05131477).

Immunology: committed to *improve standard of care*



Illustrative. For abbreviations, see slide 35.

Pipeline: *upcoming* news flow

H2 2024

- duvakitug – IBD
- rilzabrutinib – IgG4-Related disease
- Sarclisa – MM, R/R (IRAKLIA), SC
- Dupixent – CSU (US)
- rilzabrutinib – ITP (US, EU)
- tolebrutinib – SPMS (US)
- Sarclisa – NDMM, TE (HD7 study) (EU)
- Cerezyme – GD3 (US)
- Dupixent – EoE children (EU)
- Cerdelga – GD1 children (EU)

H1 2025

- Oral TNFR1si – psoriasis
- TNFa/OX40L – HS
- amlitelimab – HS
- amlitelimab – asthma
- SP0087 – rabies
- IRAK4 degrader – AD
- IRAK4 degrader – HS
- Dupixent – BP
- rilzabrutinib – ITP (JP, CN)
- tolebrutinib – SPMS (EU)
- Sarclisa – MM, R/R (IRAKLIA), SC (US, EU)
- Dupixent – COPD (JP)
- Dupixent – CSU (EU)
- fitusiran – hemophilia A/B (US)
- Sarclisa – MM, 1L TI (IMROZ) (EU, JP, CN)
- MenQuadfi – six weeks+ (US)

H2 2025

- lunsekimig – asthma
- Oral TNFR1si – RA
- AAT recombinant Fc – AATD
- SP0230 – meningitis
- SP0256 – RSV older adult
- itepekimab – COPD
- venglustat – Fabry disease
- venglustat – GD3
- tolebrutinib – PPMS
- itepekimab – COPD (US, EU)
- tolebrutinib – PPMS (US)
- SP0087 – rabies (US)
- fitusiran – hemophilia A/B (CN)
- TZIELD – DO T1D (CN)
- Rezurock – cGvHD, 3L (EU)

Key pipeline news flow only. For abbreviations, see slide 35.

Phase 2 data readout | Phase 3 data readout | Regulatory submission | Regulatory decision

Q&A session

To ask a question

By zoom 

Click on the **Raise hand** icon

Check your audio device is well connected

By phone 

Raise and lower your hand: dial *9

Unmute and mute your microphone: dial *6

Any problems? 

Email us: investor.relations@sanofi.com

Finance appendices

Sales *biopharma*

	Q3 2024 (€m)	*Change*
Dupixent	3,476	23.8%
Influenza vaccines	1,913	10.9%
Polio/Pertussis/Hib vaccines & Boosters	760	2.0%
RSV vaccines (Beyfortus)	645	381.8%
Meningitis, Travel and Endemic vaccines	485	13.1%
Lantus	431	33.8%
Toujeo	303	18.1%
Fabrazyme	253	4.0%
Lovenox	233	-1.2%
Plavix	230	8.3%
ALTUVIIIO	172	278.3%
Myozyme	168	-7.5%
Cerezyme	164	8.0%
Nexviazyme/Nexviadyme	163	53.6%
Alprolix	148	8.7%
Rezurock	131	57.8%
Praluent	126	10.4%
Thymoglobulin	121	4.1%
Sarclisa	114	23.7%
Kevzara	109	28.7%

All changes at CER and for Q3 2024 unless stated otherwise.

Currency impact

Sales (€m)



Business EPS (€)



Currency sensitivity and exposure

2024 business EPS currency sensitivity

Currency	Change	Business EPS sensitivity
US Dollar	+ 0.05 USD/EUR	- EUR 0.17
Japanese Yen	+ 5 JPY/EUR	- EUR 0.02
Chinese Yuan	+ 0.2 CNY/EUR	- EUR 0.02
Brazilian Real	+ 0.4 BRL/EUR	- EUR 0.01
Russian Ruble	+ 10 RUB/EUR	- EUR 0.01

Currency average rates

	Q3 2023	Q3 2024	% Change
EUR/USD	1.088	1.099	+1.0%
EUR/JPY	157.211	163.727	+4.1%
EUR/CNY	7.896	7.876	-0.2%
EUR/BRL	5.311	6.095	+14.7%
EUR/RUB	102.548	98.161	-4.3%

Currency exposure on Q3 2024 sales



Net debt[1]
(€m)



1. Credit ratings reaffirmed: Moody's A1/positive, S&P AA/stable, Scope AA/stable as of September 30, 2024. 2. Including derivatives used to manage net debt: €111m on December 31, 2023 and €101m on September 30, 2024. 3. Effective January 1, 2019, net debt does not include lease liabilities following the first-time application of IFRS16. 4. Includes transaction that are above a cap of €500 million per transaction (inclusive of all payments related to the transaction). 5. Including €302m use of funds from acquisition of treasury shares, -€180m of issuance of Sanofi shares and €229m of other items.

sanofi

Pipeline appendices



Pipeline: *Q3 changes*

New in

Regulatory

Submission **MenQuadfi –** Meningitis six weeks+ (US)

Phase 2

amlitelimab – Celiac disease

lunsekimig – CRSwNP

H2 2024 news flow

Regulatory submission **Cerezyme** – GD3 (US)

Regulatory decision **Cerdelga** – GD1 children (EU)

H1 2025 news flow

Phase 2 data readout **oral TNFR1si** – psoriasis

Phase 2 data readout **amlitelimab** – asthma

Phase 3 data readout **SP0087** – rabies

Regulatory submission **rilzabrutinib** – ITP (JP, CN)

Regulatory submission **tolebrutinib** – SPMS (EU)

Regulatory decision **MenQuadfi** – six weeks+ (US)

H2 2025 news flow

Regulatory decision **TZIELD** – T1D (CN)

Regulatory decision **Rezurock** – cGVHD, 3L (EU)

Designations

ODD **venglustat** – Fabry, Gaucher (JP)

Priority review **TZIELD** – T1D (CN)

Priority review **Cablivi** – aTTP (JP)

Removed in

Regulatory

Approval **Dupixent –** COPD (US, CN)

Approval **Sarclisa –** NDMM, TI (IMROZ) (US)

Phase 3

losmapimod – FSHD

MenQuadfi – six weeks+

Phase 2

oditrasertib – MS

H2 2024 news flow

Phase 2 data readout **rilzabrutinib** – wAIHA

Phase 2 data readout **amlitelimab** – asthma

Phase 3 data readout **Dupixent** – CSU (study C)

Phase 3 data readout **Dupixent** – BP

Phase 3 data readout **losmapimod** – FSHD

Phase 3 data readout **tolebrutinib** – RMS

Phase 3 data readout **tolebrutinib** – nrSPMS

Phase 3 data readout **Sarclisa** – NDMM, TE (HD7)

Regulatory submission **tolebrutinib** – RMS (US)

Regulatory submission **MenQuadfi** – six weeks+ (US)

Regulatory decision **Dupixent** – COPD (US)

Regulatory decision **Dupixent** – CRSwNP adolescents (US)

Regulatory decision **Sarclisa** – NDMM, TI (IMROZ) (US)

H1 2025 news flow

Regulatory submission **losmapimod** – FSHD (EU)

Regulatory submission **Sarclisa** – NDMM, TE (HD7) (US)

Regulatory decision **Dupixent** – COPD (CN)

H2 2025 news flow

Phase 2 data readout **oral TNFR1si** – psoriasis

Phase 3 data readout **SP0087** – rabies

Designations

ODD **Enjaymo** – CAD (US, EU, JP)

ODD **Nexviadyme** – Pompe (EU)

ODD **losmapimod** – FSHD (US)

BTD **Enjaymo** – CAD (US)

Priority review **Enjaymo** – CAD (US)

As of September 30, 2024. For collaborations (superscripted by capital letters), see slide 34. For abbreviations, see slide 35.

Pipeline: *registration* and *phase 3*

Registration

Dupixent[A]	IL4/IL13 mAb	Chronic obstructive pulmonary disease (JP)
		Chronic spontaneous urticaria (EU)
fitusiran[1]	RNAi targeting anti-thrombin	Hemophilia A and B (US, CN)
Sarclisa	CD38 mAb	MM, 1L TI (IMROZ) (EU, JP, CN)
MenQuadfi[1]	Meningococcal ACWY conjugate vaccine	Meningitis six weeks+ (US)

Phase 3

Immunology

Dupixent[A]	IL4/IL13 mAb	Bullous pemphigoid
		Chronic pruritus of unknown origin
		Chronic spontaneous urticaria (US)
		Eosinophilic gastritis
itepekimab[A]	IL33 mAb	Chronic obstructive pulmonary disease
amlitelimab	OX40L mAb	Atopic dermatitis

Rare diseases

Nexviazyme	Enzyme replacement therapy	Pompe disease infantile onset (US)
venglustat	Oral GCS inhibitor	Fabry disease
		Gaucher disease type 3
rilzabrutinib	BTK inhibitor	Immune thrombocytopenia

Other immunology

Rezurock	ROCK2 inhibitor	Chronic lung allograft dysfunction
		Chronic graft-versus-host disease, 1L
Tzield	CD3 mAb	Type 1 diabetes

Neurology

tolebrutinib	BTK inhibitor	Relapsing MS
		Primary progressive MS
		Non-relapsing secondary progressive MS
frexalimab[B,2]	CD40L mAb	Relapsing MS
		Non-relapsing secondary progressive MS
riliprubart[4]	C1s inhibitor	SOC-refractory CIDP
		IVIg-treated CIDP

Oncology

Sarclisa	CD38 mAb	MM, 1L TE (HD7)
		MM, 1L TE (IsKia)
		Smoldering MM (ITHACA)
	CD38 mAb subcutaneous	MM, relapsed/refractory (IRAKLIA)

Vaccines

SP0087	Rabies vero cell vaccine	Rabies
SP0282[C]	Extraintestinal Pathogenic E. Coli 9-valent vaccine (ExPEC9V)	E. Coli sepsis
SP0125	RSV live attenuated vaccine	RSV toddler

As of September 30, 2024. For collaborations (superscripted by capital letters), see slide 34. For abbreviations, see slide 35. Pediatric and adolescents' indication extensions are not included.
1. Currently in phase 3 in the EU. 2. Also known as SAR441344. 3. Also known as SAR445088. 4. Also known as SAR445088.

Pipeline: *phase 2*

Immunology

Dupixent[A]	IL4/IL13 mAb	Ulcerative colitis
itepekimab[A]	IL33 mAb	Bronchiectasis
amlitelimab	OX40L mAb	Alopecia areata
		Asthma
		Celiac disease
		Hidradenitis suppurativa
		Systemic sclerosis
rilzabrutinib	BTK inhibitor	Asthma
		Chronic spontaneous urticaria
		IgG4-related disease
frexalimab[B,1]	CD40L mAb	Systemic lupus erythematosus
SAR441566	Oral TNFR1 signaling inhibitor	Psoriasis
		Rheumatoid arthritis
lunsekimig[2]	IL13xTSLP Nanobody® VHH	Asthma
		Chronic rhinosinusitis with nasal polyps
eclitasertib[D,3]	RIPK1 inhibitor	Ulcerative colitis
SAR444656[E,4]	IRAK4 degrader	Atopic dermatitis
		Hidradenitis suppurativa
SAR442970	TNFaxOX40L Nanobody® VHH	Hidradenitis suppurativa
duvakitug[F,5]	TL1A mAb	Crohn's disease
		Ulcerative colitis

Other immunology

frexalimab[B,1]	CD40L mAb	Type 1 diabetes
riliprubart[6]	C1s inhibitor	Antibody-mediated rejection

Rare diseases

rilzabrutinib	BTK inhibitor	Warm autoimmune hemolytic anemia
SAR447537[7]	AAT fusion protein	Alpha-1 antitrypsin deficiency

Oncology

Sarclisa	CD38 mAb	MM, relapsed/refractory
SAR443579[G]	Trifunctional anti-CD123 NK-cell engager	Acute myeloid leukemia

Vaccines

Fluzone HD[8]	Influenza inactivated vaccine	Flu pediatric
SP0218	Yellow fever vero cell vaccine	Yellow fever
SP0202[H]	Pneumococcal 21-valent conjugate vaccine	Pneumococcal disease
SP0230	Pentavalent meningococcal ABCWY vaccine	Meningitis
SP0256	RSV mRNA vaccine	RSV older adult

As of September 30, 2024. For collaborations (superscripted by capital letters), see slide 34. For abbreviations, see slide 35. Pediatric and adolescents' indication extensions are not included.
1. Also known as SAR441344. 2. Also known as SAR443765. 3. Also known as SAR443122/DNL758. 4. Also known as KT474. 5. Also known as SAR447189/TEV'574. 6. Also known as SAR445088. 7. Formerly known as INBRX-101.
8. Also known as SP0178.

Pipeline: *phase 1*

Immunology

SAR444336	Non-beta IL2 Synthorin™	Inflammatory indication
SAR445611	CX3CR1 Nanobody® VHH	Inflammatory indication
SAR445399[1]	IL1R3 mAb	Inflammatory indication
SAR446422	CD28xOX40 bispecific Ab	Inflammatory indication

Neurology

SAR446159[I,2]	Synuclein/IGF1R mAb	Parkinson's disease

Oncology

SAR444881[J]	ILT2 mAb	Solid tumors
SAR445877[3]	PD1/IL15 fusion protein	Solid tumors
SAR445514[G]	Trifunctional anti-BCMA NK-cell engager	Relapsed/refractory MM
SAR444200	GPC3/TCR Nanobody® VHH	Solid tumors
SAR445953[K]	CEACAM5/Topo1 ADC	CRC
pegenzileukin[4]	Non-alpha IL2 Synthorin™	Cancer, in combination

Vaccines

SP0237	Flu mRNA vaccine	Flu
SP0256	hMPV/RSV mRNA vaccine	hMPV/RSV older adult
SP0268	Acne mRNA vaccine	Acne

As of September 30, 2024. For abbreviations see slide 35. For collaborations (superscripted by capital letters), see slide 34. Pediatric and adolescents' indication extensions are not included.
1. Also known as MAB212, in-licensed from MAB Discovery. 2. Also known as ABL301. 3. Also known as KD050. 4. Also known as SAR444245.

Pipeline: *regulatory designations* since 2020

Orphan drug designation

- **Dupixent** – BP, EoE (US)
- **ALTUVIIIO** – hemophilia A (US, EU)
- **fitusiran** – hemophilia A/B (US, EU)
- **rilzabrutinib** – ITP (US, EU, JP)
- **Cerdelga** – Gaucher (US)
- **Nexviazyme** – Pompe (US, JP)
- **Xenpozyme** – ASMD (US, EU, JP)
- **venglustat** – Fabry, Gaucher (US, EU, JP)
- **Rezurock** – cGvHD (US)
- **riliprubart** – CIDP (US, EU)
- **Sarclisa** – MM (US)

Fast-track designation (US)

- **itepekimab** – COPD
- **ALTUVIIIO** – hemophilia A
- **fitusiran** – hemophilia A/B
- **rilzabrutinib** – ITP
- **Nexviazyme** – Pompe
- **Xenpozyme** – ASMD
- **Venglustat** – Fabry
- **AAT recombinant Fc** – AATD
- **CD123 NKCE** – AML
- **Beyfortus** – RSV
- **mRNA RSV OA combo** – RSV
- **RSVt vaccine** – RSV
- **PCV21 vaccine** – PCV
- **Rabies vaccine** – rabies

Breakthrough therapy designation

- **Dupixent** – AD (US)
- **Dupixent** – COPD (US)
- **Dupixent** – EoE (US)
- **Rezurock** – cGvHD (US)
- **ALTUVIIIO** – hemophilia A (US, CN)
- **fitusiran** – hemophilia A/B (US)
- **Nexviazyme** – Pompe (US)
- **Xenpozyme** – ASMD (US)
- **riliprubart** – CIDP (CN)
- **Beyfortus** – RSV (US, CN)

PRIME designation (EU)

- **Xenpozyme** – ASMD
- **Beyfortus** – RSV
- **RSVt vaccine** – RSV

SAKIGAKE designation (JP)

- **Xenpozyme** – ASMD

Priority review

- **Dupixent** – AD, PN (US, CN), EoE, COPD, CRSwNP adolescents (US)
- **Kevzara** – RA (US)
- **TZIELD** – T1D (CN)
- **Rezurock** – cGvHD (US)
- **ALTUVIIIO** – hemophilia A (US)
- **Nexviazyme** – Pompe (US, JP, CN)
- **Cablivi** – aTTP (JP)
- **Xenpozyme** – ASMD (US)
- **Sarclisa** – 1L NDMM Ti (US)
- **Fexinidazole** – HAT (US)
- **Beyfortus** – RSV (CN)

Accelerated assessment

- **Dupixent** – PN (CN)
- **Xenpozyme** – ASMD (EU)
- **Beyfortus** – RSV (EU)

As of September 30, 2024. For abbreviations, see slide 35.

Collaborations

Ref	Name	Developed in collaboration with…
A	**Dupixent** **itepekimab** **Kevzara**	Regeneron
B	**frexalimab**	ImmuNext
C	**ExPEC9V Vaccine**	Janssen Pharmaceuticals
D	**eclitasertib**	Denali
E	**SAR444656**	Kymera
F	**duvakitug**	Teva Pharmaceuticals
G	**SAR443579** **SAR445514**	Innate Pharma
H	**SP0202**	SK bioscience
I	**SAR446159**	ABL Bio
J	**SAR444881**	Biond Biologics
K	**SAR445953**	Pfizer
L	**SAR444836**	Medicinova
	Beyfortus	AstraZeneca PLC
	ALTUVIIIO	Swedish Orphan Biovitrum AB (Sobi)

Abbreviations

AAT	Alpha-1-antitrypsine
AATD	Alpha-1-antitrypsine deficiency
AAV	Adeno-associated virus
Ab	Antibody
AD	Atopic dermatitis
ADC	Antibody drug conjugate
AESI	Adverse event of special interest
AML	Acute myeloid leukemia
ASMD	Acid sphingomyelinase deficiency
aTTP	Acquired thrombotic thrombocytopenic purpura
BCMA	B-cell maturation antigen
BP	Bullous pemphigoid
BTK	Bruton's tyrosine kinase
CAD	Cold agglutinin disease
CD	Cluster of differentiation
CDP	Confirmed disability progression
CEACAM5	Carcinoembryonic antigen cell adhesion molecule 5
cGvHD	Chronic graft-versus-host disease
CIDP	Chronic inflammatory demyelinating polyneuropathy
COPD	Chronic obstructive pulmonary disease
CPUO	Chronic pruritus of unknown origin
CRC	Colorectal cancer
CRSwNP	Chronic rhinosinusitis without nasal polyps
CSR	Corporate social responsibility
CSU	Chronic spontaneous urticaria
EoE	Eosinophilic esophagitis
ExPEC	Extraintestinal pathogenic *E. Coli*
FSHD	Facioscapulohumeral muscular dystrophy
GCS	Glucosylceramide synthase
GD1	Gaucher disease type 1
GD3	Gaucher disease type 3
GPC3	Glypican-3
HAT	Human African trypanosomiasis
HD	High dose
hMPV	Human metapneumovirus
HS	Hidradenitis suppurativa
IBD	Inflammatory bowel disease
IGF1R	Insulin like growth factor 1 receptor
IL	Interleukin
ILT2	Ig-like transcript 2
IRAK4	Interleukin 1 receptor associated kinase 4
ITP	Immune thrombocytopenia
ITT	Intention to treat
IVIg	Intravenous Immunoglobulin
mAb	Monoclonal antibody
MM	Multiple myeloma
mRNA	Messenger RNA
MS	Multiple sclerosis
NBRx	New to brand prescription
NDMM	Newly diagnosed multiple myeloma
NK	Natural killer
NKCE	Natural killer cell engager
nrSPMS	Non-relapsing secondary-progressive multiple sclerosis
PCV	Pneumococcal conjugate vaccine
pJIA	Polyarticular juvenile idiopathic arthritis
PMR	Polymyalgia rheumatica
PN	Prurigo nodularis
PPMS	Primary progressive multiple sclerosis
Q12W	Every 12 weeks
RA	Rheumatoid arthritis
RCT	Randomized controlled trial
RIPK1	Receptor-interacting serine/threonine-protein kinase 1
RMS	Relapsing multiple sclerosis
RNAi	RNA interference
ROCK2	Rho associated coiled-coil containing protein kinase 2
R/R	Relapsed / refractory
RSV	Respiratory syncytial virus
SAE	Serious adverse event
sJIA	Systemic juvenile idiopathic arthritis
SOC	Standard of care
TEAE	Treatment emergent adverse event
TE	Transplant eligible
TI	Transplant ineligible
TL1A	Tnf-like ligand 1A
TNF	Tumor necrosis factor
TSLP	Thymic stromal lymphopoietin
T1D	Type 1 diabetes
ULN	Upper limit of normal
wAIHA	Warm autoimmune hemolytic anemia


sanofi